证券代码：300451 证券简称：创业慧康 公告编号：2025-026 创业慧康科技股份有限公司 关于 5%以上股东部分股份解除质押及进行质押的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别风险提示： 截至本公告日，创业慧康科技股份有限公司（以下简称"公司"）5%以上 股东葛航先生累计质押 205,074,831 股公司股票，占其所持股份的 99.99%，其质 押比例没有发生变动。 创业慧康科技股份有限公司（以下简称"公司"）于近日收到 5%以上股东 葛航先生的通知，获悉葛航先生将持有的本公司部分股票与国元证券股份有限公 司（以下简称"国元证券"）办理了解除质押交易；同时与巢湖新投房地产开发 有限公司（以下简称"巢湖新投"）办理了质押手续，现将具体内容公告如下: 二、股东股份质押的基本情况 | 股东 | 是否为第一 大股东及一 | 本次质押 | 质押开始 | | 质押到 | 质权 | 占其所 持股份 | 占公司 总股份 | 是否为 | 用途 | 是否为补 | | --- | --- | --- | --- | --- | --- | --- | --- ...

Group 1: ESG Initiatives - The company has disclosed ESG reports for three consecutive years, promoting sustainable development concepts [2] - An ESG working group has been established to coordinate related departments and implement ESG initiatives [2] - The company has received multiple awards for its ESG efforts, including AAA rating from Guozheng ESG and recognition in various ESG rankings [3] Group 2: Financial Performance - The company reported a decline in revenue due to extended project bidding and implementation cycles, as well as increased impairment losses [3] - In Q1 2025, the company experienced a significant net profit decrease attributed to high fixed costs and extended payment cycles from clients [3] - The company signed 31 new HI-HIS system orders in 2024, representing a 41% year-on-year increase, indicating positive market expansion [12] Group 3: Product Development and Innovation - The company is developing an intelligent medical diagnosis system that integrates traditional Chinese medicine with AI technology [4] - The CareSync system, developed in collaboration with Philips, showcases differentiated advantages in medical insurance and traditional Chinese medicine modules [5] - The company has launched various AI-driven healthcare solutions, including the MedCopilot smart health assistant and the APTS patient tracking system [7] Group 4: Market Outlook and Strategy - The company is positioned as a leader in the healthcare information technology sector, with over 20,000 implemented projects and a client base exceeding 7,000 [14] - The healthcare information technology industry is expected to grow significantly, driven by policies like the "Healthy China 2030" initiative [9] - The company emphasizes continuous improvement in market value management and investor confidence [6] Group 5: Challenges and Risks - The company faces challenges with high accounts receivable due to lengthy payment processes, although the overall bad debt risk remains low [9] - The impact of external factors, such as market conditions and project delays, has led to fluctuations in quarterly performance [5] - The transition of AI and medical information integration into tangible profits requires time and strategic execution [13]

Core Viewpoint - The A-share smart medical sector experienced significant upward movement in the afternoon, with several companies reaching their daily limit up [1] Company Performance - Saily Medical and Runda Medical both hit the daily limit up, indicating strong investor interest and positive market sentiment [1] - Hongbo Co., Ltd. previously reached the daily limit up, showcasing a trend of rising stock prices within the sector [1] - Hongjing Technology, Chuangye Huikang, and Taikang Medical all saw their stock prices increase by over 8%, further highlighting the sector's robust performance [1]

证券之星价投圈财报分析工具显示： 分析师工具显示：证券研究员普遍预期2025年业绩在1.31亿元，每股收益均值在0.08元。 据证券之星公开数据整理，近期创业慧康（300451）发布2025年一季报。截至本报告期末，公司营业总 收入2.9亿元，同比下降22.67%，归母净利润-1564.74万元，同比下降226.6%。按单季度数据看，第一季 度营业总收入2.9亿元，同比下降22.67%，第一季度归母净利润-1564.74万元，同比下降226.6%。本报告 期创业慧康公司应收账款体量较大，当期应收账款占最新年报营业总收入比达114.01%。 本次财报公布的各项数据指标表现不尽如人意。其中，毛利率55.12%，同比增6.8%，净利率-5.06%， 同比减233.34%，销售费用、管理费用、财务费用总计7854.21万元，三费占营收比27.05%，同比增 21.54%，每股净资产2.84元，同比减4.74%，每股经营性现金流-0.1元，同比增24.16%，每股收益-0.01 元，同比减200.0% | 项目 | 2024年一季报 | 2025年一季报 | 同比增幅 | | --- | --- | --- | --- ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 6.75 [8][9]. Core Views - The company reported a revenue of RMB 290 million for Q1 2025, a year-on-year decrease of 22.67%, primarily due to the sale of a subsidiary and insufficient orders from delayed tenders [1]. - The company is expected to benefit from the recovery in demand for medical information technology as hospitals increasingly adopt AI solutions [1][3]. - The gross margin for Q1 2025 was 55.12%, an increase of 3.51 percentage points year-on-year, indicating a gradual recovery in profitability despite rising expenses due to declining revenue [2]. - The company is actively integrating AI into its medical services, launching products that cover various clinical applications and expanding its collaborative ecosystem with universities and tech companies [3]. - The company is positioned as a leader in regional health information technology and is expected to benefit from favorable government policies aimed at enhancing healthcare infrastructure [4]. Financial Projections - Revenue projections for the company are estimated at RMB 1.607 billion, RMB 1.821 billion, and RMB 2.071 billion for the years 2025, 2026, and 2027 respectively [5][7]. - The net profit attributable to the parent company is forecasted to recover to RMB 133.21 million in 2025, with further growth expected in subsequent years [7]. - The company’s estimated price-to-sales ratio for 2025 is set at 6.5 times, reflecting confidence in its product rollout and market position [5].

中证智能财讯 创业慧康（300451）4月28日披露2025年第一季度报告。公司实现营业总收入2.9亿元，同比下降22.67%；归母净利润亏损1564.74万元，上年 同期盈利1235.97万元；扣非净利润亏损2795.93万元，上年同期盈利965.83万元；经营活动产生的现金流量净额为-1.52亿元，上年同期为-2.01亿元；报告期 内，创业慧康基本每股收益为-0.01元，加权平均净资产收益率为-0.35%。 近年来市盈率变化情况（倍） 1,000 (倍) 0 46942 26.88 13088 330 dc -1,000 -2,000 -3,000 -4,000 2020-06-30 2019-12-37 2021-06-30 2021-12-37 020-12-37 n -○- 公司 -○- 行业均值 制图数据来自恒生聚源数据库 市盈率(TTM)历史分位(%) 100 ହି 90 80 70 63g71 60 53-29 50 40 39 30 30~57 20 18.6 12o26 10 4.22 0 1-06-30 1 2019-12-37 ' 020-12-37 ' <1-12-37 2n- 公司 ...

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.0100 | 0.0100 | -200 | 0.0100 | | 每股净资产（元） | 2.84 | 2.99 | -5.02 | 2.98 | | 每股公积金(元) | 1 | 1.01 | -0.99 | 0.99 | | 每股未分配利润(元) | 0.77 | 0.91 | -15.38 | 0.90 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.9 | 3.75 | -22.67 | 3.48 | | 净利润(亿元) | -0.16 | 0.12 | -233.33 | 0.1 | | 净资产收益率(%) | -0.35 | 0.27 | -229.63 | 0.23 | 本次公司不分配不转赠。 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 49654.6万股，累计占流通股比： 32.52%，较上期变 ...

证券代码：300451 证券简称：创业慧康 公告编号: 2025-025 创业慧康科技股份有限公司 关于 2025 年第一季度计提信用减值准备和资产减值准备 的公告 二、本次计提信用减值准备及资产减值准备的确认标准及计提方法 公司以单项金融工具或金融工具组合为基础评估预期信用风险和计量预期 信用损失。当以金融工具组合为基础时，公司以共同风险特征为依据，将金融工 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）根据《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》《企业会计准则》以 及公司相关会计政策的规定，在 2025 年第一季度计提了信用减值损失及资产减 值损失，现将具体情况公告如下： 一、本次计提信用减值准备和资产减值准备情况概述 1、本次计提信用减值准备和资产减值准备的原因 根据《企业会计准则》《深圳证券交易所创业板股票上市规则》等相关规定 的要求，为真实准确地反映公司截至 2025 年 3 月 31 日的财务状况和经营成果， 公司对截至 2025 年 3 月 31 日的各类资产进行了减值 ...

Financial Performance - The company's revenue for Q1 2025 was ¥290,357,981.79, a decrease of 22.67% compared to ¥375,491,442.27 in the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥15,647,403.70, representing a decline of 226.60% from a profit of ¥12,359,662.56 in the previous year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥27,959,264.39, a decrease of 389.48% compared to a profit of ¥9,658,288.80 last year[4]. - The total amount of sales and management expenses decreased by 15.70% year-on-year, while net cash flow from operating activities increased by 24.16% year-on-year[14]. - Total operating revenue for the current period was CNY 290,357,981.79, a decrease of 22.7% compared to CNY 375,491,442.27 in the previous period[20]. - The net profit for the current period was a loss of CNY 14,702,055.36, compared to a profit of CNY 14,258,715.78 in the previous period[20]. - The total comprehensive income attributable to the parent company was -15,647,403.70, compared to 12,359,640.67 in the previous period[21]. - Basic and diluted earnings per share were both -0.01, compared to 0.01 in the previous period[21]. Cash Flow and Assets - The net cash flow from operating activities was -¥152,166,660.54, an improvement of 24.16% from -¥200,644,939.83 in the previous year[4]. - The company's total assets decreased to CNY 5,564,740,193.08 from CNY 5,668,132,706.72, a decline of 1.8%[19]. - Current assets totaled CNY 3,007,557,226.42, down from CNY 3,075,922,035.12, indicating a decrease of 2.2%[19]. - The total liabilities decreased to CNY 1,102,949,579.87 from CNY 1,194,672,281.56, a reduction of 7.7%[19]. - The company's cash and cash equivalents decreased to CNY 718,220,351.12 from CNY 1,018,894,565.64, a decline of 29.5%[19]. - The cash received from the sale of goods and services was 246,234,254.96, slightly up from 246,047,168.37 in the previous period[23]. - The total cash outflow from operating activities was 425,154,234.18, down from 470,935,394.21 in the previous period[24]. - The cash and cash equivalents at the end of the period were 716,252,709.50, down from 802,849,099.37 at the end of the previous period[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 82,383[11]. - The largest shareholder, Ge Hang, holds 13.24% of shares, totaling 205,074,982 shares, with 40,000,151 shares frozen[11]. - The total number of restricted shares at the end of the reporting period is 22,430,922, with no shares released during the current period[13]. Investments and Development - The company reported a significant increase of 1135.01% in trading financial assets due to increased purchases of financial products[7]. - Development expenditures grew by 595.40% due to increased investment in new product development[7]. - Financial expenses increased by 90.31% compared to the previous year, primarily due to the expiration of large time deposits[7]. - Research and development expenses increased to CNY 79,270,029.19 from CNY 68,350,032.14, an increase of 16.5%[20]. Government Support and Market Position - The company received government subsidies amounting to ¥9,112,157.03 during the reporting period[5]. - The company is positioned to benefit from policy incentives and market expansion opportunities in the healthcare information technology sector, particularly in county-level medical community information system construction[14]. Product Development and Recognition - The company signed 8 new orders worth over 10 million during the reporting period, indicating stable demand in the healthcare information technology sector[14]. - The company has integrated its DeepSeek model with medical scenarios and launched the BsoftGPT·DeepSeek medical industry all-in-one machine, covering numerous medical applications[15]. - The "Smart Diagnosis Generation Algorithm" (BsoftGPT) was recognized in the 2024 Zhejiang Province "Smart Products" list, marking a significant technological achievement[15]. - The company aims to optimize medical resource allocation through deep integration of big data analysis and machine learning, enhancing diagnostic support for doctors and improving patient care pathways[15].

序号股票简称PE(TTM)PE(静)市净率总市值(元)32创业慧康-48.12-48.121.8983.50亿行业平均 119.02124.837.90111.52亿行业中值78.4079.253.7352.52亿1观想科技-1740.83-1624.894.2533.88亿2安硕信 息-944.00-143.2817.7865.95亿3拓维信息-927.68-380.3315.07382.22亿4国新健康-656.09-984.587.51102.15 亿5数字人-418.17-418.177.3017.39亿6中国软件-255.82-162.8017.45378.91亿7石基信息-225.15- 221.993.16232.25亿8和达科技-213.37-213.371.7412.03亿9*ST汇科-205.69-182.996.3438.78亿10延华智 能-191.62-191.629.5140.81亿11银之杰-180.41-172.3542.86222.52亿 来源：金融界 创业慧康科技股份有限公司的主营业务是医疗卫生健康信息化的建设、研发及服务创新。公司的主要产 品是医院信息化应用软件服务、公共 ...